Published in Biol Blood Marrow Transplant on October 17, 2011
Bone marrow transplantation and acute myeloid leukemia: Brazilian guidelines. Rev Bras Hematol Hemoter (2013) 0.86
Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol (2010) 2.69
Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol (2006) 2.32
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood (2011) 2.07
Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J (2003) 1.81
A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma. Br J Haematol (2007) 1.72
Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer (2007) 1.65
Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood (2006) 1.63
Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma (2009) 1.50
Questioning the role of a neutropenic diet following hematopoetic stem cell transplantation. Biol Blood Marrow Transplant (2012) 1.48
Impact of ABO mismatching on the outcomes of allogeneic related and unrelated blood and marrow stem cell transplantations for hematologic malignancies: IPD-based meta-analysis of cohort studies. Transfusion (2009) 1.47
Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia. Leuk Res (2011) 1.44
Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer (2009) 1.42
Outcome of high-dose cytarabine-based induction therapy followed by hematopoietic stem cell transplantation in acute myeloid leukemia: influence of karyotype. Leuk Lymphoma (2008) 1.39
Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol (2009) 1.28
Hematopoietic growth factors pass through the blood-brain barrier in intact rats. Exp Neurol (2007) 1.21
Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol (2008) 1.10
Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis. J Immunol (2013) 1.07
Recurrent aleukemic leukemia cutis in a patient with pre-B-cell acute lymphoblastic leukemia. J Clin Oncol (2013) 1.05
The serum-free light chain assay cannot replace 24-hour urine protein estimation in patients with plasma cell dyscrasias. Blood (2007) 1.04
DNA methylation alterations in multiple myeloma as a model for epigenetic changes in cancer. Wiley Interdiscip Rev Syst Biol Med (2010) 1.03
Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation. Antimicrob Agents Chemother (2009) 1.03
Changing epidemiology of Clostridium difficile-associated disease during stem cell transplantation. Biol Blood Marrow Transplant (2012) 1.03
Beneficial effects of hematopoietic growth factor therapy in chronic ischemic stroke in rats. Stroke (2007) 1.01
Brain repair by hematopoietic growth factors in a rat model of stroke. Stroke (2007) 0.98
Bortezomib-induced tumor lysis syndrome in multiple myeloma. Clin Lymphoma Myeloma (2006) 0.97
Immune reconstitution/immunocompetence in recipients of kidney plus hematopoietic stem/facilitating cell transplants. Transplantation (2015) 0.96
First thalidomide clinical trial in multiple myeloma: a decade. Blood (2008) 0.90
Novel therapies in multiple myeloma. Int J Hematol (2003) 0.88
Successful treatment of IgM-mediated autoimmune hemolytic anemia with bortezomib. Blood (2010) 0.86
One or two autografts for myeloma? Blood (2008) 0.85
Latexin is down-regulated in hematopoietic malignancies and restoration of expression inhibits lymphoma growth. PLoS One (2012) 0.84
Authorship limits. N Engl J Med (2002) 0.83
Clinical significance of non-Candida fungal blood isolation in patients undergoing high-risk allogeneic hematopoietic stem cell transplantation (1993-2001). Cancer (2004) 0.83
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med (2008) 0.82
Granulocyte-colony stimulating factor administration after myocardial infarction in a porcine ischemia-reperfusion model: functional and pathological effects of dose timing. Catheter Cardiovasc Interv (2007) 0.81
The role of posttransplantation maintenance chemotherapy in improving the outcome of autotransplantation in adult acute lymphoblastic leukemia. Blood (2002) 0.81
Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection. FEMS Immunol Med Microbiol (2004) 0.81
Risk of anaphylaxis with repeated courses of rasburicase: a Research on Adverse Drug Events and Reports (RADAR) project. Drug Saf (2015) 0.79
Myeloid growth factors should not be administered routinely after allogeneic hematopoietic stem-cell transplantation. J Clin Oncol (2004) 0.79
Easy to see but hard to find. N Engl J Med (2003) 0.79
Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst (2009) 0.78
Chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell transplantation: a little methotrexate goes a long way. J Clin Oncol (2002) 0.77
Best practice guidelines for the management of adverse events associated with amphotericin B lipid complex. Expert Opin Drug Saf (2010) 0.77
Haploidentical hematopoietic stem cell transplantation for graft-versus-host disease after liver transplantation. Blood (2011) 0.77
F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma. Br J Haematol (2014) 0.77
Regression of cardiac amyloid after autologous stem-cell transplantation. J Heart Lung Transplant (2009) 0.77
Definition of myeloid engraftment after allogeneic hematopoietic stem cell transplantation. Haematologica (2004) 0.77
A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings. Clin Adv Hematol Oncol (2007) 0.76
Infection--an underappreciated cause of bone pain in multiple myeloma. Br J Haematol (2003) 0.76
Multiple myeloma. Clin J Am Soc Nephrol (2006) 0.76
Varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med (2002) 0.75
Treatment for elderly patients with multiple myeloma. Lancet (2008) 0.75
Induction therapy and outcome in acute myeloid leukemia. Cancer (2010) 0.75
Routine tandem transplantation for patients with myeloma. Ann Intern Med (2003) 0.75
Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc (2010) 0.75
Total therapy 2 in treatment of multiple myeloma: questions about gene expression profiling and treatment-related mortality. J Clin Oncol (2010) 0.75
Hematopoietic stem cell transplantation from unrelated donors for acute leukemia. Blood (2008) 0.75
High-dose chemotherapy with autotransplantation in AL amyloidosis: a flawed meta-analysis. Biol Blood Marrow Transplant (2009) 0.75
Sirolimus-containing graft-versus-host disease prophylaxis in patients with lymphoma. J Clin Oncol (2009) 0.75
PET-CT in lung cancer: data discrepancies. Thorax (2011) 0.75
Treatment of relapsed and refractory multiple myeloma. Curr Treat Options Oncol (2003) 0.75
Sustained hematologic and central nervous system remission with single-agent denileukin diftitox in refractory adult T-cell leukemia/lymphoma. Clin Lymphoma Myeloma (2007) 0.75
Variability of cyclosporine concentrations by HPLC and TDX monoclonal assay methods, application of a correction factor, and description of a novel clinical approach to determine the practical consequences of changing assay technique. Clin Transplant (2012) 0.75
Recent developments and future directions in the treatment of multiple myeloma. Cancer Biother Radiopharm (2003) 0.75
Diffuse large B-cell lymphoma: is there a place for autologous hematopoietic stem cell transplant in first remission in the era of chemo-immunotherapy? Leuk Lymphoma (2012) 0.75
Idarubicin appears equivalent to dose-intense daunorubicin for remission induction in patients with acute myeloid leukemia. Leuk Res (2013) 0.75
Dose-intense etoposide-cyclophosphamide without stem cell transplantation for patients with intermediate and high cytogenetic risk primary refractory and relapsed acute myeloid leukemia. Leuk Res (2013) 0.75
Lenalidomide in myeloma. Curr Treat Options Oncol (2007) 0.75
Instability of immunophenotype in plasma cell myeloma. Am J Clin Pathol (2008) 0.75
Re-use of the original infusional induction chemotherapy as salvage therapy in myeloma patients relapsing after one autograft. Hematology (2005) 0.75
Biologic agent activity in chronic lymphocytic leukemia: a framework for future therapies. Leuk Lymphoma (2011) 0.75